Meu SciELO
Serviços Personalizados
Artigo
Indicadores
- Citado por SciELO
Links relacionados
- Similares em SciELO
Compartilhar
MediSur
versão On-line ISSN 1727-897X
Resumo
LAURENCIO VALLINA, Sandra Caridad et al. Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021. Medisur [online]. 2024, vol.22, n.1, pp. 120-126. Epub 28-Fev-2024. ISSN 1727-897X.
ABSTRACT
Foundation
SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country.
Objective
to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients.
Methods
a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records.
Results
morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%).
Conclusions
resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases.
Palavras-chave : Coronavirus infections; immunologic factors; morbidity; mortality; treatment outcome.